SCHEMBL16183610

SCHEMBL16183610

CNc1nc(-c2cccnc2)nc2c(C)c(-c3ccc(C)cc3)ccc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 3/20 0.54
▸ CYP3A4 P08684 3/20 0.54
▸ CLK4 Q9HAZ1 3/20 0.54
▸ CYP2D6 P10635 2/20 0.54
▸ CYP2C19 P33261 2/20 0.54
▸ HSD17B10 Q99714 2/20 0.54
▸ CYP2C9 P11712 1/20 0.54
▸ MAPT P10636 5/20 0.48
▸ MAPK1 P28482 2/20 0.48
▸ HTT P42858 2/20 0.48
▸ MEN1 O00255 3/20 0.46
▸ KMT2A Q03164 3/20 0.46
▸ GBA1 P04062 2/20 0.44
▸ ALDH1A1 P00352 4/20 0.44
▸ SMN1; SMN2 Q16637 3/20 0.44
▸ TP53 P04637 2/20 0.44
▸ NPSR1 Q6W5P4 2/20 0.44
▸ NFKB1 P19838 1/20 0.44
▸ NFKB2 Q00653 1/20 0.44
▸ RELA Q04206 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14475094 0.93 CYP1A2 (0.63) CYP1A2CYP3A4CLK4CYP2D6CYP2C19
SCHEMBL14474520 0.92 CYP1A2 (0.53) CYP1A2CYP3A4CLK4CYP2D6CYP2C19
SCHEMBL16183606 0.92 CYP1A2 (0.55) CYP1A2CYP3A4CLK4CYP2D6CYP2C19
SCHEMBL18022986 0.91 CYP3A4 (0.52) CYP1A2CYP3A4CLK4CYP2D6CYP2C19
SCHEMBL16184266 0.91 CYP1A2 (0.52) CYP1A2CYP3A4CLK4CYP2D6CYP2C19
SCHEMBL14475080 0.91 CYP1A2 (0.52) CYP1A2CYP3A4CLK4CYP2D6CYP2C19
SCHEMBL14475184 0.89 CYP3A4 (0.50) CYP1A2CYP3A4CLK4CYP2D6CYP2C19
SCHEMBL16183860 0.89 CYP3A4 (0.52) CYP1A2CYP3A4CLK4CYP2D6CYP2C19
SCHEMBL14727723 0.88 ABCG2 (0.49) CYP1A2CYP3A4CLK4CYP2D6CYP2C19
SCHEMBL14474641 0.86 CYP1A2 (0.49) CYP1A2CYP3A4CLK4CYP2D6CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3056207-A1 THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE Otsuka Pharmaceutical Co., Ltd. (JP) 2016-08-17 — — EP disclosed
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE PPP2CA, PPP4C, PPP3CB CYP1A2 2971/4885CYP3A4 4456/4885CLK4 1084/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback